Evaluation of CisBio ELISA for Chromogranin A Measurement.
Journal
The journal of applied laboratory medicine
ISSN: 2576-9456
Titre abrégé: J Appl Lab Med
Pays: England
ID NLM: 101693884
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
31
08
2018
accepted:
29
01
2019
entrez:
23
10
2019
pubmed:
23
10
2019
medline:
10
9
2020
Statut:
ppublish
Résumé
Chromogranin A (CgA) is a nonspecific marker for the presence of neuroendocrine tumors and neuroendocrine differentiation. The objective of this study was to evaluate the performance of the CisBio CgA ELISA. Precision, linearity, limit of blank, and recovery of the CisBio CgA ELISA were evaluated. Seventy waste serum samples obtained from the clinical laboratory at Memorial Sloan Kettering Cancer Center were analyzed by the CisBio CgA ELISA. Results were compared to those obtained from a reference laboratory that used a proprietary ELISA for serum CgA measurement. Paired waste plasma samples were also collected from 24 of these patients to assess possible differences between CgA in serum and plasma. Finally, a preliminary reference range study was performed with samples from healthy volunteers in serum (n = 60) and plasma (n = 60). Within-run and between-run precision ranged from 3.0% to 5.1% and 4.8% to 12.9%, respectively. The limit of blank was 2.4 ng/mL. Recovery ranged from 88% to 102%. A statistically significant bias was observed when the CisBio CgA assay results were compared to those of a reference laboratory. Comparison of the 2 assays yielded a slope of 9.05, intercept of -18.0, and a correlation coefficient of 0.955. CgA values in serum correlated well to values measured in plasma. The analytical performance of the CisBio CgA ELISA was acceptable. However, CgA results are method-specific owing to lack of standardization and use of different antibodies. This lack of standardization results in several challenges for the clinical laboratory when evaluating a CgA assay.
Sections du résumé
BACKGROUND
Chromogranin A (CgA) is a nonspecific marker for the presence of neuroendocrine tumors and neuroendocrine differentiation. The objective of this study was to evaluate the performance of the CisBio CgA ELISA.
METHODS
Precision, linearity, limit of blank, and recovery of the CisBio CgA ELISA were evaluated. Seventy waste serum samples obtained from the clinical laboratory at Memorial Sloan Kettering Cancer Center were analyzed by the CisBio CgA ELISA. Results were compared to those obtained from a reference laboratory that used a proprietary ELISA for serum CgA measurement. Paired waste plasma samples were also collected from 24 of these patients to assess possible differences between CgA in serum and plasma. Finally, a preliminary reference range study was performed with samples from healthy volunteers in serum (n = 60) and plasma (n = 60).
RESULTS
Within-run and between-run precision ranged from 3.0% to 5.1% and 4.8% to 12.9%, respectively. The limit of blank was 2.4 ng/mL. Recovery ranged from 88% to 102%. A statistically significant bias was observed when the CisBio CgA assay results were compared to those of a reference laboratory. Comparison of the 2 assays yielded a slope of 9.05, intercept of -18.0, and a correlation coefficient of 0.955. CgA values in serum correlated well to values measured in plasma.
CONCLUSIONS
The analytical performance of the CisBio CgA ELISA was acceptable. However, CgA results are method-specific owing to lack of standardization and use of different antibodies. This lack of standardization results in several challenges for the clinical laboratory when evaluating a CgA assay.
Identifiants
pubmed: 31639703
pii: jalm.2018.028027
doi: 10.1373/jalm.2018.028027
pmc: PMC7485006
mid: NIHMS1624048
doi:
Substances chimiques
Biomarkers, Tumor
0
Chromogranin A
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
11-18Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 American Association for Clinical Chemistry.
Références
Horm Metab Res. 2011 Nov;43(12):832-7
pubmed: 22009449
Prostate. 1997 Jan 1;30(1):1-6
pubmed: 9018329
Endocr Relat Cancer. 2018 Jan;25(1):R11-R29
pubmed: 29066503
J Clin Oncol. 2016 Nov 10;34(32):3906-3913
pubmed: 27621394
Ann Surg Oncol. 2010 Sep;17(9):2427-43
pubmed: 20217257
Ann Oncol. 2017 Jul 1;28(7):1569-1575
pubmed: 28444114
Int J Urol. 2008 May;15(5):423-8
pubmed: 18452460
Eur Urol. 2004 May;45(5):586-92; discussion 592
pubmed: 15082200
Clin Biochem. 2014 Jan;47(1-2):87-91
pubmed: 24201067
Future Oncol. 2018 Jun;14(13):1233-1235
pubmed: 29712494
J Endocrinol. 2003 May;177(2):337-41
pubmed: 12740022
Pract Lab Med. 2015 Mar 10;1:5-11
pubmed: 28932793
Eur J Endocrinol. 2004 Mar;150(3):299-303
pubmed: 15012614
Crit Rev Oncol Hematol. 2014 Oct;92(1):11-24
pubmed: 24952997
Sci Rep. 2018 Oct 18;8(1):15442
pubmed: 30337589
Prostate Cancer Prostatic Dis. 2018 Sep;21(3):431-437
pubmed: 29858590
Int J Biol Markers. 2004 Oct-Dec;19(4):295-304
pubmed: 15646836
Endocr Connect. 2016 Sep;5(5):174-87
pubmed: 27582247
J Gastrointestin Liver Dis. 2014 Dec;23(4):419-24
pubmed: 25532001